Primary and acquired platinum-resistance among women with high grade serous ovarian cancer

Gynecologic Oncology

Volumn 142, Issue 2, 2016, Pages 225-230

  Slaughter, Katrina ^a   Holman, Laura L ^a   Thomas, Eric L ^a   Gunderson, Camille C ^a   Lauer, Jacob K ^a   Ding, Kai ^b   McMeekin, D Scott ^a   Moore, Kathleen M ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Acquired platinum resistance; Ovarian cancer; Primary platinum resistance; Survival

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; CANCER GRADING; CYSTADENOCARCINOMA, SEROUS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84969715303     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.05.020     Document Type: Article

References (16)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin. 65 (2015), 5–29.
2. [2] Davis, A., Tinker, A.V., Friedlander, M., “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?. Gynecol. Oncol. 133 (2014), 624–631.
3. [3] Bookman, M.A., Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The oncologist. 4 (1999), 87–94.
4. [4] Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 9 (1991), 389–393.
5. [5] Gore, M.E., Fryatt, I., Wiltshaw, E., Dawson, T., Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36 (1990), 207–211.
6. [6] Rose, P.G., Fusco, N., Fluellen, L., Rodriguez, M., Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 16 (1998), 1494–1497.
7. [7] Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45 (2009), 228–247.
8. [8] Rustin, G.J., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). International Journal of Gynecological Cancer: Official journal of the International Gynecological Cancer Society 21 (2011), 419–423.
9. [9] Thigpen, T., A rational approach to the management of recurrent or persistent ovarian carcinoma. Clin. Obstet. Gynecol. 55 (2012), 114–130.
10. [10] Gordon, A.N., Fleagle, J.T., Guthrie, D., Parkin, D.E., Gore, M.E., Lacave, A.J., Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 19 (2001), 3312–3322.
11. [11] Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 32 (2014), 1302–1308.
12. [12] Food, U.S., Administration, Drug, Bevacizumab solution in combination with paclitaxel. Approved Drugs, 2014 [cited 2015, December 23] Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm423159.htmInformationOnDrugs/ApprovedDrugs/ucm423159.htm.
13. [13] Cannistra, S.A., Matulonis, U.A., Penson, R.T., Hambleton, J., Dupont, J., Mackey, H., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 25 (2007), 5180–5186.
14. [14] Kaye, S.B., Lubinski, J., Matulonis, U., Ang, J.E., Gourley, C., Karlan, B.Y., et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30 (2012), 372–379.
15. [15] Domchek, S.M., Aghajanian, C., Shapira-Frommer, R., Schmutzler, R.K., Audeh, M.W., Friedlander, M., et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol. Oncol 140 (2016), 199–203.
16. [16] Colombo, N., Kutarska, E., Dimopoulos, M., Bae, D.S., Rzepka-Gorska, I., Bidzinski, M., et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30 (2012), 3841–3847.